Concepedia
Clinical Cancer Research · 2011 · 359 citations · 16 references
PD 0332991 warrants phase II testing at 125 mg once daily, at which dose neutropenia was the sole significant toxicity.
16
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations
World Health Organization, Solid Tumors, Cancer Management +17
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
David W. Fry, Patricia J. Harvey, Paul R. Keller et al. · Molecular Cancer Therapeutics · 2004 · 1.2K citations
A p16 <sup>INK4a</sup> -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Thomas Wölfel, Martina Hauer, Jörg Schneider et al. · Science · 1995 · 1.1K citations
Cdk Phosphorylation Triggers Sequential Intramolecular Interactions that Progressively Block Rb Functions as Cells Move through G1
J. William Harbour, Robin X Luo, Angeline Dei Santi et al. · Cell · 1999 · 1.1K citations · Full text
Signal Transduction, Signaling Pathway, Cell Regulation +11
Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
Lena E. Friberg, Anja Henningsson, Hugo Maas et al. · Journal of Clinical Oncology · 2002 · 523 citations